Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field
Little Alder BioPharmaceuticals $ALDR has racked up a slate of positive late-stage data for its Phase III study of a new CGRP migraine drug, but …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
